Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Ian Fendley
BB Biotech holds steady in the second quarter
Major headwinds caused by various factors such as the talk of the US federal government imposing drug price controls and the general impression that the bull market is on its last leg weighed on investor sentiment in the healthcare sector during the second quarter. BB Biotech shares were not completely immune to these developments and delivered a return of 1.2% in EUR for the second quarter and 8.2% for the first half of 2018.
Biotech in the fight against cancer
Big players in the healthcare sector are desperate to differentiate their approved ‘checkpoint inhibitors’ (a drug that unleashes an immune system attack on cancer cells) by combining their use with conventional chemotherapy or other new drugs. Biotechnology firms are developing many of these next-generation combination agents as well as continuing to strengthen their positions in treatments for more niche medical problems. This makes for an interesting area for investors.
Biotech outlook: Increasing strength of innovation in 2018
This in turn will enable continued investment in their research pipelines and catapult them to the next level of success, secured by increasingly diverse sources of growth. Acquisitions and alliances will remain an additional source of diversification and subsequent growth.
BB Biotech - double digit return and record dividend
With a total return for BB Biotech’s shareholders of 23.1% in CHF and 13.1% in EUR buoyed by the euro’s substantial appreciation against the dollar, BB Biotech delivered a strong performance in 2017. The underlying portfolio performed well, ending the year up 23.4% in CHF, 12.5% in EUR and 29.2% in USD – which is 7.5% ahead of the Nasdaq Biotech Index .Consolidated, but not yet audited, full year 2017 data showed a net gain of CHF 688 mn..
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Ian
Contact Ian, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack